Oxurion Temettü

Temettü kriter kontrolleri 0/6

Oxurion şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

Geri Alım Getirisi

Toplam Hissedar Getirisi	0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

What Type Of Returns Would Oxurion's(EBR:OXUR) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Feb 01

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: OXUR şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: OXUR şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Oxurion Piyasaya Karşı Temettü Getirisi

OXUR temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OXUR)	n/a
Pazarın Alt %25'i (BE)	2.7%
Pazarın En İyi %25'i (BE)	7.3%
Sektör Ortalaması (Biotechs)	1.5%
Analist tahmini (OXUR) (3 yıla kadar)	n/a

Önemli Temettü: OXUR şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, OXUR şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: OXUR şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: OXUR herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Oxurion Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

First half 2024 earnings released

Oxurion NV (ENXTBR:OXUR) signed a letter of intent to acquire 80% stake in Contract Research Organisation for €9.8 million.

Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)

New minor risk - Financial data availability

Oxurion NV to Report Fiscal Year 2023 Results on Apr 15, 2024

Oxurion NV, Annual General Meeting, May 07, 2024

Oxurion Announces CEO Changes

Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

First half 2023 earnings released: €0.02 loss per share (vs €0.32 loss in 1H 2022)

Oxurion NV to Report First Half, 2023 Results on Sep 29, 2023

Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular Edema

High number of new and inexperienced directors

Less than half of directors are independent

Oxurion NV Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis

Oxurion NV Announces Interim Analysis for KALAHARI Trial

Price target decreased to €1.25

Oxurion NV Announces Preclinical Presentation on THR-149 at KININ2022

Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

Price target increased to €10.00

Oxurion NV, Annual General Meeting, May 02, 2023

Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Full year 2021 earnings: Revenues exceed analyst expectations

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Oxurion NV Announces New Data on THR-149 Phase 2 Clinical Trial in DME At the Angiogenesis, Exudation, and Degeneration 2022 Conference

Oxurion Provides Update on Clinical Pipeline Progress

Oxurion NV announced that it has received €10 million in funding from Pontifax Ltd., Kreos Capital Management (UK) Limited

OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)

OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Full year 2020 earnings released

Oxurion NV announced that it expects to receive €30 million in funding from Negma Group Ltd.

Full year 2020 earnings released: €0.75 loss per share (vs €1.35 loss in FY 2019)

Oxurion NV to Report Fiscal Year 2020 Final Results on Apr 05, 2021

What Type Of Returns Would Oxurion's(EBR:OXUR) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Oxurion Nv Appoints Prof Alan Stitt as Chief Scientific Officer

How Is Oxurion's (EBR:OXUR) CEO Compensated?

New 90-day high: €2.90

Oxurion NV to Report Fiscal Year 2021 Results on Mar 17, 2022

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

Oxurion NV Announces Executive Changes

Baron Philippe Vlerick, Non-Executive member of the Board of ThromboGenics NV acquired 3.6% stake in ThromboGenics NV (ENXTBR:THR).

New 90-day low: €2.45

Oxurion NV(ENXTBR:OXUR) dropped from S&P Global BMI Index

First half earnings released

Here's What We Learned About The CEO Pay At Oxurion NV (EBR:OXUR)

New 90-day low - €2.57

Oxurion (EBR:OXUR) Share Prices Have Dropped 43% In The Last Year

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin